Effects of Atorvastatin Treatment on sICAM-1 and Plasma Nitric Oxide Levels in Hypercholesterolemic Subjects

Abstract

This study investigated the behavior of soluble intercellular adhesion molecule-1 (sICAM-1) and serum nitric oxide (NO) products, nitrite/nitrate (NO 2-NO,-), in subjects with primary hypercholesterolemia (HCh) without other risk factors and atherosclerosis. The effect of a short-term cholesterol-lowering treatment with atorvastatin, an HMG-CoA reductase inhibitor, on the levels of sICAM-1 and NO2-/NO3 were also investigated. After 4 weeks of placebo administration, 40 HCh (15 males and 25 females) were randomized in 2 groups: 20 subjects (atorvastatin group) received 10 mg/day of atorvastatin and the remaining 20 (placebo group) continued to take placebo. At baseline and after 4 and 12 weeks of atorvastatin or placebo administration, serum sICAM-1 and NO2-/NO3-levels were evaluated. The basal levels of these parameters were compared with those of 20 healthy subjects (C), matched for sex and age. Hypercholesterolemic subjects showed sICAM-1 and NO2-/NO3-basal values that were higher (331.7 ± 60.3 ng/mL vs. 202.3 ± 32.3 ng/mL, p<0.001) and lower (10.4 ± 2.5 μmol/L vs. 20.7 ± 4.4 μmol/L, p<0.01) than controls. No correlation between sICAM-1 or NO products and plasma cholesterol values was found, whereas there was an inverse correlation between sICAM-1 and NO2-/NO3-levels. Atorvastatin administration significantly decreased sICAM-1 and increased NO2-/NO3-levels, however these changes were not correlated with the reduction of plasma cholesterol. These data support the hypothesize that patients with HCh with no signs of arterial lesions, may have latent atherosclerosis, expressed as an increase of sICAM-1 and decrease in NO product levels. An improvement in the levels of these parameters after a short-time treatment with atorvastatin was also demonstrated.

Keywords

Hypercholesterolemia sICAM-1 Nitric oxide Atorvastatin Endothelial activation Atherosclerosis.

References

1. Ross R . The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 1993;362:801-801.

2. Rubanyi GM . The role of endothelium in cardiovascular homeostasis and diseases. J Cardiovasc Pharmacol 1993;22 (suppl 4):S1-S1.

3. Chowienczyk PJ , Watts GF , Cockcroft JR , Ritter JM . Impaired endothelium-dependent vasodilation of forearm resistance vessels in hypercholesterolemia. Lancet 1992;340:1430-1430.

4. Celermajer DS . Endothelial dysfunction: Does it matter? It is reversible? JAm Coll Cardiol 1997;30:325-325.

5. Hackman A , Abe Y , Insull W Jr , et al. Levels of soluble cell adhesion molecules in patients with dyslipidemia. Circulation 1996;93:1334-1334.

6. Hwang SJ , Ballantyne CM , Sharrett R , et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases. Circulation 1997;96:4219-4219.

7. Harrison DG . Cellular and molecular mechanism of endothelial cell dysfunction. J Clin Invest 2000;105:1631-1631.

8. Moncada S , Palmer RMJ , Higgs EA . Nitric oxide: Physiology and pathophysiology and pharmacology. Pharmacol Rev 1991;43:109-109.

9. Radomski MW , Palmer RMJ , Moncada S . Endogenous nitric oxide inhibits human platelet adhesion to the vascular endothelium. Lancet 1987;2:1057-1057.

10.

10. Garg UC , Hassid A . Nitric oxide generating vasodilators and 8-bromo-cyclic GMP inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989;83:1974-1974.

11.

11. Spiecker M , Darius H , Kaboth K , et al. Differential regulation of endothelial cell adhesion molecules expression by nitric oxide donors and antioxidants. J Leuk Biol 1998;63:732-732.

12.

12. Muenzel T , Heitzer T , Harrison DG . The physiology and pathophysiology of the nitric oxide/superoxide system. Herz 1997;22:158-158.

13.

13. Tanaka S , Yashiro A , Nakashima Y , et al. Plasma nitrite/nitrate level is inversely correlated with plasma low-density lipoprotein cholesterol level. Clin Cardiol 1997;20:361-361.

14.

14. Rosselli M , Inthur B , Keller PJ , et al. Circulating nitric oxide (nitrite/nitrate) levels in postmenopausal women substituted with 17p-estradiolo and norethisteronre acetate. A two-year follow-up study. Hypertension 1995;25 (part 2):848-848.

15.

15. Feron 0 , Dessy C , Moniotte S , et al. Hypercholesterolemia decreases nitric oxide production by promoting the interaction of caveolin and endothelial nitric oxide synthase. J Clin Invest 1999;103:879-879.

16.

16. Ohara Y , Peterson TE , Harrison DG . Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 1993;91:2545-2545.

17.

17. O'Driscoll G , Green D , Taylor RR . Simvastatin, an HMG-coenzyme A reductase inhibitor improves endothelial function within 1 month. Circulation 1997;95:1126-1126.

18.

18. Nakashima Y , Toyokawa T , Tanaka S , et al. Simvastatin increase plasma NO2-and NO3-levels in patients with hypercholesterolemia. Atherosclerosis 1996; 127:43-43.

19.

19. Feron 0 , Dessy C , Desager JP , Balligand JL . Hydroxy methyl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation 2001;103:113-113.

20.

20. Sardo MA , Castaldo M , Cinquegrani M , et al. Effects of simvastatin on sICAM-1 and sE-selectin levels in hypercholesterolemia subjects. Atherosclerosis 2001;155:143-143.

21.

21. Friedewald WT , Levy RJ , Fredrickson DS . Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-499.

22.

22. Green LC , Wagner DA , Glogowski J , et al. Analysis of nitrite and (15N) nitrate in biological fluids. Ann Biochem 1982;126:131-131.

23.

23. Kureishi Y , Luo Z , Shijima I , et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase AKT and promotes angiogenesis in normocholesterolemic animals. Nature Med 2000;6:1004-1004.

24.

24. Wagner AH , Kohler T , Rucksholoss U , et al. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscl Thromb Vasc Biol 2000;20:61-61.

25.

25. Huie RE , Padmaja S . Reaction of nitric oxide with superoxide anion. Free Radical Res Commun 1993;18:195-195.

26.

26. Schreck R , Rieber P , Baeuerle PA . Reactive oxygen intermediates as widely used messengers in the activation of the NF-kB transcription factor and HYV-1. Eur Mol Biol Organ J 1991; 10:2247-2247.

27.

27. De Caterina R , Libby P , Peng H-B , et al. Nitric oxide decreases cytokine-induced endothelial activation. J Clin Invest 1995;96:60-60.